Detalhe da pesquisa
1.
Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial.
Lancet Oncol
; 23(9): 1156-1166, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35934010
2.
Enhancer reprogramming in PRC2-deficient malignant peripheral nerve sheath tumors induces a targetable de-differentiated state.
Acta Neuropathol
; 142(3): 565-590, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34283254
3.
Assessment of Clinical Response Following Atezolizumab and Bevacizumab Treatment in Patients With Neuroendocrine Tumors: A Nonrandomized Clinical Trial.
JAMA Oncol
; 8(6): 904-909, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35389428
4.
The immune landscape of undifferentiated pleomorphic sarcoma.
Front Oncol
; 12: 1008484, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36313661
5.
Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver Metastases.
Clin Cancer Res
; 27(11): 3039-3049, 2021 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33811152
6.
Procedural Requirements and Recommendations for Multiplex Immunofluorescence Tyramide Signal Amplification Assays to Support Translational Oncology Studies.
Cancers (Basel)
; 12(2)2020 Jan 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-31972974